this is around the normal volume for the stock after the drug was approved and until the traders got in prior to the par pharma generic news (they may of gotten the info from the court filing prior to omeros notification).
It is low float. If you consider the 64% institutional, only about 13 million shares left as float.
Sentiment: Strong Buy
Very small decrease in what is an amazingly large short position. I think shorts can stay the course until around 20, but we are talking 33 days to cover at normal share volumes which of course are not what happens if there is a squeeze. Every little bit helps, I wish I had doubled down after the last earnings report drop. I expected a larger drop but it recovered almost immediately which is a very good sign.
Both price cuts are legitimate. They reflect a slightly lower market for even the very brightest of small companies with increasing credit burden, scrutiny and market volatility.
Tc is talking about what may be possible. I agree with him that laws may pass that Impact omidria. But the law would fall short to blame omeros since they are not paying an incentive for docs to use omidria.
that's a HUGE leap and the Omidriaassure program is nothing like what Valeant is doing. Quit with the moronic scare tactics based on ZERO facts
For the logic impaired. Valeant and others use the business practice like OMIDRIAssure, combined with other questionable business practices to create a real questionable business model. So IF Congress and other government agencies decide to go after Valeant they won't use a scalpel against Valeant they will use a chainsaw against the whole industry. If you want an apple to apple comparison look at what happen to the financial industry. Most banks were using their new freedoms in a perfectly safe manner, but a few got greedy and corrupt and now all the banks have to pay for the other banks sins. Next year is going to be a political hotbed and you can never predict which issue will catch the voters attention, but seniors, a major voting block, have an interest in drug pricing. So that is why I said OMIDRIAssure MAY become illegal, not because Omeros is doing something wrong or evil, but because the business practice will be tarnished for the sins of others.
Omidria is the only FDA-approved drug - there is absolutely no relation to what Valeant was doing, which was circumventing doctors' prescriptions and/or insurance company rules in order to get their drug sold over a cheaper generic or other FDA-approved alternative. Beyond that, this is a one-time charge (vs a potentially recurring prescription) at cost that is reasonable given the benefit it provides the doctors. Any comparison to Valeant's issues is laughable.
Kind is the reversal of the generic issue par pharma, where they are arguing the accessibility as it relates to cost.
I can see it being an issue when there are multiple drugs and the higher price drug gives some kind of reward versus the cheaper drug to the patient or physician. For the federal funded programs the Medicaid patients will have no to low copay (Medicaid is state program but they get federal funds) and as for the Medicare programs most have supplemental or hmo.
If dr d had said they were giving incentives we might of been included with the Valent headlines
Actually OMIDRIAssure may become illegal. Congress and other government agencies are looking into these type of programs after the dust up with Valeant and others. Below is from a WSJ article a few years ago about how drugs companies are using a grey area in he law. The question has become how "independent" are these charitable organizations. This whole area of pharma business practices is getting in the spotlight, if anything will change only time will tell.
Kuhn said that some companies have been concerned that they might violate federal anti-kickback laws, which prohibit drug companies from giving financial assistance to people enrolled in federally funded public health insurance programs to encourage them to take one drug over another. But the HHS Office of Inspector General in 2002 said it would not seek civil or criminal penalties against PSI participants. Further, it said that PSI "interposes an independent charitable organization between donors and patients in a manner that effectively insulates" patients and physicians from being influenced by donations.